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Abstract
Genetic mutations of FUS have been linked to many diseases including Amyotrophic Lateral Sclerosis (ALS) and
Frontotemporal Lobar Degeneration. A primate specific and polymorphic retrotransposon of the SINE-VNTR-Alu (SVA) family
is present upstream of the FUS gene. Here we have demonstrated that this retrotransposon can act as a classical
transcriptional regulatory domain in the context of a reporter gene construct both in vitro in the human SK-N-AS
neuroblastoma cell line and in vivo in a chick embryo model. We have also demonstrated that the SVA is composed of
multiple distinct regulatory domains, one of which is a variable number tandem repeat (VNTR). The ability of the SVA and its
component parts to direct reporter gene expression supported a hypothesis that this region could direct differential FUS
expression in vivo. The SVA may therefore contribute to the modulation of FUS expression exhibited in and associated with
neurological disorders including ALS where FUS regulation may be an important parameter in progression of the disease. As
VNTRs are often clinical associates for disease progression we determined the extent of polymorphism within the SVA. In
total 2 variants of the SVA were identified based within a central VNTR. Preliminary analysis addressed the association of
these SVA variants within a small sporadic ALS cohort but did not reach statistical significance, although we did not include
other parameters such as SNPs within the SVA or an environmental factor in this analysis. The latter may be particularly
important as the transcriptional and epigenetic properties of the SVA are likely to be directed by the environment of the
cell.
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Introduction
Genetic variation which alters the primary sequence of a protein
has allowed tremendous insight into underlying mechanisms
associated with predisposition, progression and severity of diseases.
However, most genetic variation identified in candidate gene and
genome wide association studies associated with disease processes
is within non coding regions. This has led to a greater analysis and
emphasis on the importance of gene-environment interactions in
which tissue specific or stimulus inducible challenges target
transcriptional regulatory domains to alter mRNA abundance
underlying the disease process. Amyotrophic Lateral Sclerosis
(ALS) is one disease in which such a mechanism may play a
significant role, because although about 5% of ALS is familial
(FALS), in most cases of ALS the patient has no family history of
the disease (sporadic ALS; SALS). Nevertheless, cases with a
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significant genetic component can give us insight into which signal
transduction pathways may be compromised in the development
of the disease as they can highlight processes which may be targets
for the challenges which trigger ALS.
FUS (Fused in sarcoma) found on chromosome 16p11.2 is a
RNA binding protein. Mutations in its coding exons have been
identified in some cases of FALS and it is therefore a candidate for
genetic association with ALS [1]. The number of ALS cases
attributed to mutations in the FUS gene is small; FUS mutations
are present but rare in SALS at around 1% [2–5] and found in
only 3–5% of FALS [6,7]. Although rare genetic mutations in the
FUS gene account only for a small proportion of apparently non-
familial SALS, FUS positive inclusions have been found in the
anterior horn of the spinal cord in SALS patients without FUS
mutations, and in non-SOD1 FALS [8]. Whilst FUS is ubiqui-
tously expressed, the levels of FUS may be critical for cell viability,
and modulation of expression may be associated with the initiation
or progression of ALS suggesting a role for the environment in
modulation of levels of FUS gene expression. A differential
response in gene expression to the stimulus could be modulated by
the genotype thus allowing for a Gene x Environment interaction
(GxE) in the initiation or progression of conditions such as ALS in
which FUS is implicated. This would be consistent with a recent
mouse model in which over expression of wildtype FUS caused
progressive motor neuron degeneration in an age- and dose-
dependent fashion [9]. We therefore undertook an analysis of the
FUS locus to determine potential regions of genomic variation that
are candidate domains to direct differential gene expression in
response to environmental challenge.
Although it is difficult to accurately predict the regulatory
domains for a particular gene other than the proximal promoter
(often 0.5 to 1 kb upstream of the transcriptional start site), our
group and others have demonstrated important domains for gene
regulation can reside in both the most evolutionary conserved
regions (ECRs) which are non-coding [10–12] and the highly
polymorphic and often rapidly evolving variable number tandem
repeats (VNTRs) [13–19]. In both cases the ECR or VNTR can
be tens of thousands of bases from the major transcriptional start
of a gene [20]. Genetic variants in both classes of domains are
often clinical correlates of disease progression [10,14,21]. The
searches for potential areas involved in transcriptional regulation
can be aided by utilisation of ENCODE (encyclopaedia of DNA
elements) data searching for the presence of potential transcription
factor binding sites, active histones or DNase 1 hypersensitivity
clusters [22,23]. We performed such a bioinformatic analysis of the
FUS locus and highlighted one large VNTR region 59 of the FUS
gene which overlapped active histones and other ENCODE data
suggesting it might act as a transcriptional regulatory domain
(Figure S1). Further analysis demonstrated the VNTR was part of
a larger primate specific retrotransposon termed a SINE-VNTR-
Alu (SVA) element. SVAs are the most recent family of
retrotransposons to insert into the human genome with 2676
SVAs identified in the Hg19 release from UCSC genome browser
[24]. There is considerable interest, but limited data available
describing the role of retrotransposon elements in human health
with 96 disease causing insertions having been identified as of 2012
[25]. In the ageing brain somatic retrotransposition has been
demonstrated and this plasticity in the genome has been suggested
to play a role in the diseases associated with an ageing population
[26,27]. Furthermore in tumours it has been shown that epigenetic
modulation of retrotransposons in general including SVAs can
vary in cancer progression, specifically, alterations in methylation
patterns have been detected [28]. The SINE region of the SVA
derived from the human endogenous retrovirus K10 (HERV-K10)
has been used to classify SVAs into subtypes A-F with the age of
each subtype ranging from an estimated 13.6 million years for the
oldest (SVA A) to 3.2 million years for the youngest (SVA F) [29].
An additional subtype was identified that contains sequence from
exon 1 of the MAST2 gene and associated CpG island at the 59
end of the SVA and was named CpG-SVA, MAST2 SVA or SVA
F1 [30–32]. The SVA in the FUS gene is classified as subtype D, or
SVA D. Based on data from the UCSC browser using the human
genome sequence release 19 as the reference genome (http://
genome.ucsc.edu/), this particular element is found only in
humans and chimpanzees amongst the primates.
Retroviruses, exogenous and endogenous, have been linked
with ALS [33]. An increased prevalence of reverse transcriptase
(RT), a key enzyme in the retrovirus life cycle converting RNA to
DNA, has been observed in the serum of patients with SALS
[34,35]. In the second study [34] the elevated RT enzyme levels
were interpreted as indicative of involvement of an endogenous
retrovirus rather than an exogenous retrovirus as blood relatives
also had elevated levels whereas spouses were the same as controls.
A further study has implicated retrotransposons as having a role in
ALS because HERV-K transcripts and RT protein were detected
in autopsy brain tissue of patients with ALS along with the
aberrant expression of TDP-43 [36]. These authors suggested
targeting of activated genome-encoded retroviral elements may
open new prospects for the treatment of ALS. The cellular
environment that led to this increased expression of HERV-K
transcripts and RT may be a global change that could influence
the expression or activity of other retrotransposons in the genome
for example epigenetic changes across mulitple loci of retro-
transposons have been shown in cancer [28]. We hypothesised
that the SVA upstream of the FUS gene could be one such
domain. The activation does not have to lead to retrotransposition
for it to affect gene expression in adjacent genomic loci, as
alteration of epigenetic factors may modulate any transcriptional
properties embedded within the SVA. Our hypothesis is that the
SVA domain could have significant potential to modulate gene
expression at the FUS locus and that the variation in the VNTR
could support differential gene expression based on the challenge
that the cell receives. Therefore we addressed the ability of the
SVA D 59 of the FUS gene to act as a classical transcriptional
regulator in reporter gene constructs in vitro and in vivo. We further
addressed its potential polymorphic variation and whether such
variation acts as a predisposing factor for ALS.
Materials and Methods
Cell culture
The human neuroblastoma cell line SK-N-AS (American Type
Culture Collection Resource Centre stock number CRL-2137) was
maintained in Dulbecco’s Modified Eagle’s Medium (Sigma,
D5672), 10% foetal bovine serum (ThermoScientific/Hyclone,),
1% penicillin/streptomycin (100 U/ml, 100 mg/ml; Sigma
P0781), 1%(v/v) Non-Essential Amino Acids (Sigma, M7145)
and 1%(v/v) 200 mM L-glutamine (Sigma, D7513), in 5% CO2 at
37uC.
Generation of reporter gene constructs for use in vitro
All regions were amplified by high fidelity PCR from pooled
mixed gender human genomic DNA preparations (G3041
Promega, USA) using Pfu DNA polymerase (Promega, USA).
Primers used incorporated restriction sites for directional cloning
within an added octameric linker sequence (underlined below,
forward: NheI, reverse: BglII) and the first two PCR-cycles were
performed at annealing temperatures matching template-specific
Regulatory Properties of a SVA in the FUS Promoter
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sequences exclusively. The following primer sets were used: SVA
(1240/1190bps, long/short alleles), (forward) 59-
GGCTAGCCGTGACTATTGCATACCTTGCCCCAGGCC-
39, (reverse) 59- GAGATCTCGGAGAGGTTGTCATGGTA-
CACAGACTGG-39; TR/VNTR (862/812 bp, long/short al-
leles), (forward) 59-GGCTAGCCCAGTTTTCCCTCAGACC-
CAGC-39, (reverse) 59-
GAGATCTCGTTGGGGGTAAGGTCACAGATCAACAGG-
39. Amplified fragments were cloned into the firefly luciferase
reporter gene expressing vector pGL3P, containing a SV40
minimal promoter element (Promega, USA). Correct cloning
and sequence were verified by bi-directional sequencing using
standardised primers.
Endogenous FUS expression in SK-N-AS cell line was
confirmed by semi-quantitative RT-PCR from purified total
RNA preparations using the following primers: (forward) 59-
AGGTGACTGTTTAGTGGGTAGGTC-39 and (reverse) 59-
ATAGCCGGACACAGTATCTCACAC-39.
Cell transfection and dual luciferase assay
SK-N-AS cells were co-transfected with test constructs (firefly
luciferase reporter gene) and an internal control construct,
pMLuc-2 (renilla luciferase reporter gene; Novagen, USA) using
TurboFect Transfection Reagent (ThermoScientific/ Fermentas,
R0531) according to manufacturer’s protocol in 24-well plate
format. Transfectant was removed after 4 hours of incubation and
exchanged with fresh medium and subsequent luciferase activity
assays performed after 48 hours of incubation.
Luciferase activity of reporter constructs was measured using a
Dual Luciferase Reporter Assay System (Promega, USA) using
lysates from transfected cultured cells according to manufacturer’s
instructions. Assays were carried out on a Glomax 96-well
microplate Luminometer (Promega, USA) using 20 ml of cell
lysate. Measurements were averaged from 6-fold replicates to
minimize pipetting errors and repeated at least three times to
confirm results. Statistical analyses were performed using MSExcel
software and a one tailed t-test to measure the significance of fold
activity of the FUS SVA and TR/VNTR over the minimal
promoter of the pGL3P vector *P,0.05, ***P,0.001, and to
compare the activity of the alleles of the SVA and the TR/VNTR
to each other # P,0.05.
Construction of plasmids for in vivo fluorescent models
Generation of tomato reporter plasmid. Tomato gene
sequence was PCR amplified from pG-tdTomato (a kind gift from
Marco Marcello, University of Liverpool) using primers Tomato
UP 59- ATAGGAATTCCGTGTACGGTGGGAGGTCTA-39
and Tomato DOWN 59- GGCCGTCGACATCATTT-
TACGTTTCTCGTTC-39 which introduce Eco RI and Sal I
restriction sites, upstream and downstream respectively, for
directional cloning into the plasmid pIRESGFP (kind gift from
John Gilthorpe). The pIRES-GFP cassette was removed using
EcoRI and XhoI restriction sites and replaced by the Tomato
reporter gene, such that it was downstream of the chick b-actin
promoter.
Generation of human FUS L-SVA and L- TR/VNTR in vivo
reporter plasmids. The generation of the proximal FUS
promoter reporter plasmid is described elsewhere (Kursheed et al.
in preparation). Briefly, human FUS promoter sequences (2160/+
84) were cloned into the SacI/BamHI sites of the promoter-less
reporter vector phrGFP (Stratagene,UK) upstream of the GFP
reporter gene. Identity was confirmed by sequencing and plasmid
named ppGFP. The FUS SVA and isolated TR/VNTR sequenc-
es, both isotype ‘long’ allele were amplified by PCR from L-SVA
and L-TR/VNTR reporter plasmids described above using
standard Phusion polymerase conditions (NEB Biolabs) with the
addition of 3% DMSO (v/v). The primers used are outlined below
and included NsiI and XbaI restriction enzyme sites (underlined) to
facilitate directional cloning: SVA UP 59-TTGCATGCATGT-
GACTATTGCATACCTTGC-39and SVA DN 59-GACGTC-
TAGAGGAGAGGTTGTCATGGTACA-39 and TR/VNTR
UP 59-TTGCATGCATCAGTTTTCCCTCAGACCCAG-
39and TR/VNTR DN59-GACGTCTAGAGTTGGGGG-
TAAGGTCACAGA-39. The resulting products were cloned into
the Nsil/Xbal sites of FUS ppGFP and sequences were verified, this
created L-SVA ppGFP and L-TR/VNTR ppGFP.
Manipulation of chick embryos
Fertile chick eggs were incubated at 37.8uC for two days until
they were approximately developmental stage 14 HH. 2–3 ml of
albumen was removed and a window was cut in the egg. Embryos
were staged according to Hamburger and Hamilton [37]. In those
at stage 11–14 the vitelline membrane was removed to aid
manipulation of the embryo. The lumen of the neural tube was
injected with a solution containing 2–5 mg/ml of test DNA
reporter plasmid, 1 mg/ml of Tomato plasmid (control for
successful injection) in PBS containing 1 mM MgCl2 and
0.2%(v/v) fast green (to help visualisation). Injections were
undertaken with a pulled micropipette made from a borosilicate
capillary (Warner Instruments). Post-injection, DNA was immedi-
ately electroporated into the cells of the neural tube; gold plated
electrodes of 3 mm length (Harvard Apparatus) were placed either
side of the embryo with an internal gap of 5 mm and 5650 ms
square wave pulses with 100 ms gaps were delivered. Electropo-
rated embryos were incubated at 37.8uC for 48 hours until they
were approximately developmental stage E5 and then assessed for
expression of plasmid DNAs. Electroporated embryos were
dissected out and photographed using epifluorescent microscopy.
Genotyping the VNTR of the FUS SVA
The following primers; forward 59CAGTTTTCCCTCA-
GACCCAGCAC 39 and reverse 59GAGCTGTTGGGTA-
CACCTCCCAGAC 39 were used to amplify the TR/VNTR
sequences within the SVA 59of the FUS gene in a SALS and
matched controls cohort from the King’s College London MND
DNA Bank by PCR. All participants gave ethically approved
written consent to participate in the study, which was approved by
the South London and Maudsley Ethics Committee (reference
222/02). The templates were 5 ng of genomic DNA from the
SALS patient samples and matched controls and amplification
reactions used Taq polymerase with FailSafe 2XD buffer (Cambio)
following the recommended protocol. The products were run on a
1.2% agarose gel stained with GelRed Nucleic Acid Stain
(Biotium) and visualised using a UV transilluminator (BioDoc-it
Imaging System).
Results
The SVA 59 to the FUS gene is a transcriptional regulator
Analysis of the FUS gene +/215 kb identified a large repetitive
region approximately 10 kb 59 of the FUS gene and 20 kb from
the 59 end of the PRSS36 gene using the UCSC genome browser
(Figure 1A). This repetitive region is part of a larger SVA D
element. ENCODE data demonstrated that this SVA overlapped
or was adjacent to many features that suggested that it could be
regulatory in nature. These included; 1) an area of active histones,
H3K4Me1, which are associated with transcription factor binding
in genome-wide datasets, 2) human ESTs have been identified
Regulatory Properties of a SVA in the FUS Promoter
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which originate and are transcribed in both directions from this
location and 3) DNase 1 clusters are located on each side of the
SVA (Figure S1). The SVA is present in chimpanzees and humans
but not in other primates and does not contain the 59 CCCTCT
hexamer repeat found in a canonical SVA (Figure 1B). Analysis
using rVista through the ECR browser identified 146 conserved
transcription factor binding sites between the human and
chimpanzee SVA sequences; which included a variety of factors
such as members of the Sp and GATA families.
The region encompassing this SVA D and the central repetitive
region were prepared by PCR from commercially available DNA
(Promega), cloned and the sequence validated. On sequence
analysis two distinct alleles of the SVA were observed, which
differed from one another by one copy of the repeat from the
central repetitive region and could therefore be classed as a
VNTR. SVAs in general can contain one or two central VNTRs
sharing similarities in their sequences but which are distinct from
each other. The occurrence of two central VNTRs as opposed to
one is seen more frequently in the younger subtypes (D, E, F and
F1). The FUS SVA appears to belong to the group of SVAs that
contain two central repetitive regions as opposed to one. It is in the
second of these repetitive regions where the difference between the
two alleles is seen. Such variation in only the 2nd domain of the
central repeats has been noted in another SVA D located
upstream of the PARK7 gene, which supports gene expression in
a reporter gene model in vitro [24]. We therefore termed the two
repetitive regions in the FUS SVA a tandem repeat (TR) and a
VNTR when analysed individually and a TR/VNTR when in
combination. The two alleles identified were named long (L) and
short (S) and the sequence of the TR/VNTR within the SVA is
shown in Figure 1C with the additional repeat in the long allele
underlined.
Reporter gene constructs were prepared in the pGL3P vector
including both variants of the SVA (L-SVA and S-SVA), and the
isolated central TR/VNTR (L-TR/VNTR and S-TR/VNTR)
(Figure 1B). It was not possible to test the TR and VNTR as
separate independent domains as they could not be amplified
individually due to their location adjacent to each other,
Figure 1. Loci of FUS gene and structure of SVA D located upstream. A- Schematic of loci of the FUS gene located on chromosome 16.
According to UCSC genome browser (Hg18) there are several transcripts with nearly all originating at the transcriptional start site indicated in the
diagram. There is a SVA D 9.9kb upstream of this transcriptional start site of the FUS gene. This SVA D is present in human and chimpanzees but not
other primates. ENCODE data from the genome browser UCSC is summarised indicating the presence of DNase1 clusters, expressed sequence tags
(ESTs) and histone modifications associated with enhancers and promoter at this locus. B- Schematic showing the components contributing to the
structure of the SVA D located upstream of the FUS gene. It contains an Alu-like sequence, a tandem repeat (TR) consisting of 7 copies of a 37–40 bp
repeat, a variable number tandem repeat (VNTR) consisting of 3–4 copies of a 37–50 bp repeat and a SINE. This particular SVA is missing the CCCTCT
hexamer repeat seen at the 59 end of a canonical SVA. The fragments cloned into the reporter gene vector (pGL3P) are shown by the black line for the
SVA (length 1240/1190 bp) and the grey line for the TR/VNTR (length 862/812 bp). C- Sequence of the 7 copies of the 59 TR and 3–4 copies of the 39
VNTR. The repeat underlined is the additional copy found in the long allele which is absent in the short allele of the SVA (sequence in UCSC genome
browser corresponds to long allele).
doi:10.1371/journal.pone.0090833.g001
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preventing design of a specific primer that would not bind to more
than one of the repeats in the FUS TR or VNTR. Activity of the
constructs was measured in the human neuroblastoma cell line
SK-N-AS, which was shown by RT-PCR to express endogenous
FUS, data not shown. Statistically significant differences were
observed in the levels of reporter gene expression supported by the
complete SVA or the TR/VNTR compared to the minimal SV40
promoter alone in pGL3P vector (S-SVA p,0.05, L-SVA p,0.05,
S-TR/VNTR p,0.001 and L-TR/VNTR p,0.05). Both alleles
of the complete SVA repressed reporter gene expression whilst
both alleles of the TR/VNTR were activators in this cell line,
demonstrating that the SVA may contain multiple and distinct
regulatory domains, one of which is a dominant repressor in SK-
N-AS cells (Figure 2). When comparing the long and short TR/
VNTR constructs no significant difference in the level of reporter
gene activity observed was noted, however there was a small but
significant difference in the levels of reporter gene expression when
these variants were contained within the complete SVA sequence
(p,0.05). In both the SVA and TR/VNTR constructs it was the
long variant that showed lower activity when compared to the
short.
We have previously demonstrated that human specific VNTRs
can support tissue specific expression patterns in mouse transgenic
models during development [38]. We wanted to address a similar
model for the SVA but rather than use a mouse model we used the
more convenient and practical chick embryo model [39,40]. The
SVA and TR/VNTR (long allele) domains as used above in the
SK-N-AS cell line were inserted into a reporter gene vector we
had developed to allow us to visualise activity via hrGFP in the
chick embryo model. Briefly the reporter vector phrGFP
contained the proximal human FUS promoter 2160 of the major
transcriptional start site to +84 cloned upstream of hrGFP, the
TR/VNTR and SVA sequences were inserted immediately
upstream of the promoter sequence. The minimal FUS promoter
does not support gene expression in this model and therefore any
marker gene expression is dependent on the cloned regulator.
The test plasmid was injected into the neural tube and then
transfected into cells by electroporation; thus only one side of the
neural tube should be transfected. The reporter gene construct was
co-injected with an internal control, the tomato reporter plasmid
directed by the chick b-actin promoter; the latter acts as an
internal control marker for cells which have been successfully
transfected. In this manner we addressed the activity and tissue
specificity of the L-SVA and the L-TR/VNTR reporter. The
series of FUS reporter gene constructs were injected into the
developing embryo at embryonic stage 14HH and activity
analysed at stage 22HH. Endogenous chick FUS expression was
demonstrated by RT-PCR at this point in the development of the
embryo (data not shown). The proximal FUS promoter alone did
not support sufficient reporter gene expression to be observed in
our assay (Figure 3B). However, both the L-SVA and L-TR/
VNTR reporter gene constructs supported expression; which was
readily observed in the neural tube of the chick embryo (Figure 3E
and 3H respectively).
Genetic variation in the FUS SVA
It has been previously demonstrated that VNTRs with distinct
copy numbers of the repeating element can not only support
tissue specific and stimulus inducible reporter gene activity but
can also be differentially associated with genetic predisposition to
a specific disorder, for example the human transporters for
serotonin and dopamine [14,18,41,42]. We therefore expanded
the analysis of the polymorphic variation associated with the
VNTR within the SVA, addressing this in a cohort of 241
individuals with SALS and 228 matched controls. The genetic
variation was analysed by agarose gel electrophoresis of the PCR
Figure 2. The SVA and the VNTR within show distinct functional properties in a reporter gene construct. Reporter gene constructs
containing each allele of the FUS SVA and TR/VNTR (long and short) were transfected into the neuroblastoma cell line, SK-N-AS. The fold values of
activity demonstrated by each construct compared to pGL3P normalised to the internal control (pMLuc-2) to account for differences in transfection
efficiency are displayed. Both alleles when tested as a complete SVA showed repressive function and were significantly different to each other. When
the alleles were tested as a smaller fragment consisting of the central TR/VNTR region they both showed enhancer properties. One tailed t-test was
used to measure the significance of fold activity of the FUS SVA and TR/VNTR over the minimal promoter of the pGL3P vector *P,0.05, ***P,0.001,
and to compare the activity of the alleles of the SVA and the TR/VNTR to each other # P,0.05.
doi:10.1371/journal.pone.0090833.g002
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fragments spanning the TR/VNTR region of the SVA. We
found there were only two alleles that could be determined in
this cohort (this analysis cannot determine SNP or small
insertion/deletion variation within the SVA) (Figure 4A). We
confirmed the sequence from both a L and S allele after gel
purification; this demonstrated that the L allele corresponded to
the sequence found in the UCSC browser for the VNTR of this
SVA element (Figure 1C). The two alleles also matched the
variants originally identified when cloning the SVA for reporter
gene studies from commercially available DNA (Promega). The
following genotype frequencies were observed in the SALS
cohort 45.6% LL, 39% LS and 15.4% SS and 46.9% LL, 42.1%
LS and 11% SS in the matched controls (Figure 4B). Although
there was a small difference of 4.4% between the frequency of SS
individuals in the SALS cohort compared to the matched
controls this was found not to be significant when analysed using
CLUMP [43]. The T1 26N table statistic from CLUMP [43]
was p= 0.36 and the clumped 262 T4 p-value was 0.33, both
from 10,000 simulations. CLUMP simulations allow for the small
cell values present in sparse 26N tables such as those in highly
multiallelic repeat loci and prevent inflation of the test statistics
from generating false positive results.
Discussion
We have demonstrated that a retrotransposon, of the SVA
family, 59 of the FUS gene is both polymorphic and a
transcriptional regulator domain. The SVA acted as a classical
regulatory domain when analysed in reporter gene constructs in
vitro and in vivo. This data would suggest that the SVA can affect
FUS gene expression patterns by multiple mechanisms without the
requirement for retrotransposition and that distinct polymorphic
variants could act to direct differential regulation in response to
the same environmental challenges. The transcription factor
complement within the cell will be based on a specific stimulus
the cell is receiving at any given moment and this synergistic tissue
specific and stimulus inducible challenge may result in altering the
complement of transcription factors able to direct function from
the SVA. There can also be epigenetic variation across SVA
elements dependent on the environment for example a change in
methylation across retrotransposons was identified in cancer [28].
Both the alleles of the complete SVA and the TR/VNTR
domain of the SVA were tested in an in vitro reporter gene assay.
Distinct from standalone VNTR domains which we have
previously addressed, the repetitive region of this particular SVA
Figure 3. Demonstration of the activity of the L-SVA and L-VNTR presumptive transcriptional regulator in the chick embryo model
at stage 22 HH. Chick embryos were electroporated with either a FUS proximal promoter GFP (ppGFP) reporter construct (A–C), L-SVA ppGFP-
reporter (D–F) or L-TR/VNTR ppGFP-reporter (G–I) at stage 14HH and GFP expression analysed 48 hr later (stage 22HH). Expression could not be
detected in the neural tube from the FUS proximal promoter sequences alone (B), however when either the L-SVA (E) or L-TR/VNTR (H) sequences
were included, GFP reporter gene expression could readily be seen. Panels A, D and G show the corresponding bright field images. Panels C, F and I
show the identical fields taken with a red filter to demonstrate the extent of successful electroporation of the neural tube using a control tomato
marker expression plasmid. Scale bar in B is 2 mm and in E & H is 1 mm.
doi:10.1371/journal.pone.0090833.g003
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D contains two adjacent domains comprised of a TR and a VNTR
and it was this composite element that was tested in the reporter
gene assay. It is interesting that while both the L and S TR/VNTR
regions were enhancers of activity, the intact L and S SVA acted as
a repressor in the SK-N-AS cell line. This suggests that in addition
to the activator region in the TR/VNTR the SVA contains a
strong active silencer element, flanking this central TR/VNTR
region, which is functional in the SK-N-AS neuroblastoma cell
line. There are multiple conserved transcription factors within the
FUS SVA sequence however the action of repressors or enhancers
are often determined by the factors available in the cell at any
given time therefore further analysis will be required to determine
the action of specific transcription factors on the SVA. An
alternative explanation for the difference in activity between the
TR/VNTR and SVA may be due to proximity of the TR/VNTR
domain to the reporter gene when part of the complete SVA
element affecting its ability to enhance expression.
There was no significant difference between the activities of the
two alleles of the TR/VNTR when tested alone, but there was a
significant difference between the two alleles when tested as part of
the complete SVA (p,0.05). To further validate the regulatory
properties of this domain we tested its properties in the neural tube
of the chick embryo. Although FUS is a ubiquitously expressed
protein this region of the embryo contains motor neurons which
are the appropriate cell type to test a domain that might be
involved in ALS. As in the cell line model the long allele of the
TR/VNTR domain acted as an activator but in this model the
long allele of the SVA also demonstrated activator properties
which were not exhibited in vitro. This would be consistent with our
previous analyses of VNTRs from both the serotonin and the
dopamine transporters demonstrating cell line specific properties
in reporter gene constructs [41,44,45] and the intron 2 VNTR
from the human serotonin transporter having tissue specific
properties in a transgenic mouse model [38]. This particular
system of analysing the transcriptional properties of a domain is
not quantitative therefore we cannot compare the amount of
expression activated by the TR/VNTR and the intact SVA.
Our functional data demonstrated the potential for the FUS
SVA to act as a transcriptional regulatory element, however only a
small difference in the function of the two alleles was observed,
although we hypothesise such a difference could be increased upon
exposure of the cell to specific challenges. Nevertheless the
genotype of the SVA could be a factor which associates with a
predisposition to disorders such as ALS. We therefore performed a
genotype analysis of the TR/VNTR of the SVA in a SALS and
the control cohort from the King’s College London MND DNA
Bank. This demonstrated two major alleles which we termed L and
S and which correlated to those identified in the cloned
commercial DNA (Promega). The frequencies of LL, LS and SS
were not found to be significantly different in the sporadic cases
compared to the matched controls, although a minor difference
could be seen between the frequency of individuals with a SS
genotype in SALS and control (15.4% vs 11%), when analysed
using CLUMP [43]. This may also reflect in part that FUS
mutations themselves are rare in SALS (1%) and that we need to
address an environmental challenge as a modulator of FUS
expression. A much larger cohort will be required to validate such
variation as an association in the SALS cohort. Our study would
not determine the potential SNP or indel variation in the SVA;
such variation may be significant for both clinical association with
disease and transcriptional properties of the SVA. Precedent for
this exists; the long and short alleles of the VNTR within the
promoter of the human serotonin transporter gene, in this
example there is a genetic association based on GxE interactions,
namely a SNP in the long allele makes it clinically similar to the
short ‘risk’ allele in genetic associations [46,47].
In summary we have determined a novel primate tissue specific
regulator that could play a role in FUS transcriptional regulation.
This regulation could be modified by a number of environmental
challenges including the changes correlated with the increased RT
activity seen in the serum of patients that could affect the
epigenetic structure of the FUS locus. This regulation could be
further modulated by genetic variation in the SVA apart from the
VNTR variant observed in this analysis thus allowing for a GxE
interaction in any of the diseases’ in which FUS is implicated.
Supporting Information
Figure S1 Locus of FUS gene in the UCSC genome
browser. The FUS gene is located on chromosome 16p11.2 and
this image is showing 11 kb 59 of the transcriptional start site of the
gene. The region highlighted in the black box corresponds to the
SVA D upstream of the FUS gene. From the ENCODE data
shown in the image there are DNase hypersensitivity clusters,
transcription factor binding and enhancer and promoter associ-
ated histone marks (H3K4Me1) in the region of this SVA D
indicating this is an active region of chromatin.
(TIFF)
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